Mounjaro Gains Access to China’s National Health Insurance, Expanding Diabetes Treatment Options
Table of Contents
Inclusion in China’s national reimbursement list will significantly broaden access to Mounjaro for patients with type 2 diabetes, though increased sales volume may be tempered by negotiated lower prices. The announcement, made Sunday by the national health authority, marks a major step for Eli Lilly (LLY) in the world’s most populous nation.
Expanding Access in a Massive Market
the addition of Mounjaro to China’s national health insurance system, effective January 1st, will make the once-weekly injection therapy available to a vast population of 1.4 billion people. This move underscores China’s commitment to improving healthcare access for its citizens. However, industry observers note that inclusion on the national reimbursement list typically results in reduced drug prices, a common trade-off for increased market penetration.
Following Ozempic’s Path
Mounjaro’s launch in China occurred in January of this year, following a similar trajectory to Ozempic, a competing diabetes therapy from Novo Nordisk (NEW_B). Ozempic was first introduced to the Chinese market in 2021, but wasn’t added to the national reimbursement list until 2022. According to Novo Nordisk’s annual report, Ozempic sales in China reached 5.76 billion Danish crowns – equivalent to approximately $898.5 million – in 2024.
Pricing Negotiations and Broader Applications
Eli Lilly has not yet publicly disclosed the price of Mounjaro under China’s reimbursement scheme,as this figure is subject to ongoing negotiations with the goverment. Beyond diabetes, Mounjaro is also approved in China for the treatment of obesity and obstructive sleep apnea, potentially expanding its reach within the healthcare system.
Global Momentum for Mounjaro
A senior company official revealed in an October conference call that Eli Lilly has observed “initial ramp-up” in markets outside the U.S. where Mounjaro has been launched. Key markets during the second quarter included China, Brazil, Mexico, and India. “Since than, we have also seen performance increase in the third quarter in these markets and continued very strong performance globally,” the official stated. This suggests a growing international demand for the drug, despite the pricing pressures inherent in national health insurance systems.
(1 dollar = 6.4105 Danish kroner)
Here’s a substantive news report answering the “Five Ws and How”:
What: Eli Lilly’s Mounjaro, a treatment for type 2 diabetes, obesity, and obstructive sleep apnea, has been added to China’s National Health Insurance reimbursement list.
why: This inclusion will significantly expand access to Mounjaro for the 1.4 billion people in China, aligning with the country’s goal of improving healthcare access. however, it also means Eli Lilly will likely have to negotiate lower prices for the drug.
Who: The key players are Eli Lilly (LLY), the manufacturer of Mounjaro; the National Health Authority of China, which made the announcement; Novo Nordisk (NEW_B), whose similar drug Ozempic followed a comparable path to reimbursement; and the 1.4 billion potential patients in China.
How: Mounjaro was launched in China in January 2024. Following a similar pattern to Ozempic, which was added to the reimbursement list in 2022 after its 2021 launch, Mounjaro’s inclusion will take effect January 1st. The price will be determined through ongoing negotiations between Eli
